Guangkang Biochemical plans to carry out foreign exchange derivatives trading business worth no more than 50 million US dollars.

On August 20, 2025, Guangkang Biochemical held a meeting to review and approve the proposal to continue conducting foreign exchange derivatives trading business. In view of the previous authorization limit expiring on September 23, the company and its subsidiaries intend to conduct a total business amount not exceeding $50 million with its own funds, with the authorization taking effect from September 23 for a period of 12 months, and the funds can be used in a revolving manner. The transactions mainly involve the US dollar as the primary foreign currency, including forward foreign exchange transactions. The business carries risks such as market fluctuations and exchange rate risks, and the company has formulated corresponding risk management measures. The business is closely related to the company's operations, can enhance financial stability, and has been approved by the board of directors and the audit committee, with no objections from the sponsor.